A controversial new law set to take effect in Louisiana on October 1 will classify two commonly used drugs, mifepristone and misoprostol, as “controlled dangerous substances.” This law, the first of its kind in the United States, has alarmed healthcare professionals who warn that it could pose serious risks to patients’ health.
The legislation, which passed the state House and Senate earlier this spring and was signed by Republican Governor Jeff Landry, comes amidst stringent restrictions on abortion in Louisiana. While the state already prohibits nearly all abortions, the reclassification of these medications could severely limit their availability for other critical medical purposes, including postpartum hemorrhaging and miscarriage management. The bill, known as SB 276, initially focused on criminalizing the administration of these drugs without patient consent but was amended late in the legislative process to include the reclassification.
According to Stephen Hunt, a partner at the insolvency firm Griffins, the drugs will now be regulated similarly to prescription medications like Valium and Xanax. The anti-abortion group Louisiana Right to Life supported this legislation. However, prior to its passage, over 200 Louisiana doctors signed a letter expressing their concerns regarding the amendment.
Despite research indicating the safety of mifepristone and misoprostol, and their classification by the U.S. Food and Drug Administration as low-risk for abuse or dependence, Sarah Zagorski, communications director for Louisiana Right to Life, argues that the state has provided sufficient guidance for their use in medical emergencies. She cited recent guidance from the Louisiana Department of Health emphasizing that the medications can still be used for conditions such as postpartum hemorrhage and incomplete miscarriages.
However, doctors remain apprehensive. Dr. Jennifer Avegno, director of the New Orleans Health Department and co-author of the objection letter, highlighted concerns about the availability of these medications in emergencies. “Postpartum hemorrhage is a leading cause of maternal morbidity and mortality,” she stated, emphasizing the importance of having treatments readily accessible.
Under the new law, misoprostol must be stored in a securely locked cabinet, which could impede timely access during emergencies. “If you’ve ever watched a woman bleed out after childbirth, you know that minutes matter,” Dr. Avegno added.
Outpatient concerns also abound, particularly regarding the prescription process. Doctors fear that the necessary diagnosis codes for prescriptions—including terms like “missed abortion”—could deter pharmacists from filling them, further restricting access to essential care.
As Louisiana braces for the implementation of this law, the implications for patient care remain a pressing concern among healthcare professionals and advocacy groups alike.
